Recombinant insulin lisargine(Hefei Tianmai Biotech)

重组赖精胰岛素（合肥天麦）

Report date: 2025/03/26 20:01:25

Base Information

Drug NameRecombinant insulin lisargine(Hefei Tianmai Biotech)
Drug Alias Name重组赖精胰岛素注射液
ClassificationBiologics > Protein drugs > Recombinant protein > Recombinant hormone
Mechanisms of ActionInsulin receptor agonists
TargetsInsulin receptor
Therapy Area/IndicationsDiabetes Mellitus
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesHefei Tianmai Biotechnology Development Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesHefei Tianmai Biotechnology Development Co Ltd
Inactive CompaniesN/A
Active IndicationsDiabetes Mellitus
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A